← Back to Search

LY3454738 (Reference Formulation) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to 85 days post dose
Awards & highlights

Study Summary

This trial will test the safety, dose, and effectiveness of a new drug and measure how long it stays in the body. It will last about 17 wks.

Who is the study for?
This trial is for healthy individuals who are interested in helping to test a new drug called LY3454738. Participants will be involved in the study for about 17 weeks, including screening time.Check my eligibility
What is being tested?
The study is testing how much of the drug LY3454738 enters the bloodstream and how quickly it's eliminated when administered under the skin. It compares two different formulations of this drug.See study design
What are the potential side effects?
While specific side effects aren't listed, participants' safety and tolerance to LY3454738 will be monitored, with any experienced side effects being recorded throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to 85 days post dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to 85 days post dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3454738
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3454738

Trial Design

2Treatment groups
Experimental Treatment
Group I: LY3454738 (Test Formulation)Experimental Treatment1 Intervention
Group II: LY3454738 (Reference Formulation)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3454738
2018
Completed Phase 1
~130

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,619 Previous Clinical Trials
3,206,569 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,715 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible for me to register for this clinical experiment?

"In order to be eligible for the trial, applicants must fall within 18-65 years of age and possess good general health. There are 30 slots available in total."

Answered by AI

Are individuals currently being recruited to enroll in this research program?

"Per the data on clinicaltrials.gov, this particular medical trial is no longer recruiting patients for participation. Initially posted on September 1st 2024, it was last updated December 8th 2023. Although this study has ended recruitment efforts, there are 808 other trials that remain open to receiving candidates at present."

Answered by AI

Is this research project admitting subjects who are over 30 years of age?

"This medical trial is open to adults aged 18 years or more, but younger than 65."

Answered by AI

What potential risks should be considered prior to administering LY3454738 (Test Formulation)?

"As this is an early stage trial, only limited data exists about the safety and efficacy of LY3454738 (Test Formulation). This has led our team to rate its safety at 1 on a scale from one to three."

Answered by AI

Who else is applying?

What site did they apply to?
ICON Early Phase Services
What portion of applicants met pre-screening criteria?
Met criteria
~0 spots leftby May 2024